GlobalData on MSN12d
Gilead and LEO Pharma link on programmes for inflammatory conditions
Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...
Yahoo Finance12d
Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory Disease Therapies
Gilead will pay LEO Pharma $250 million upfront under the arrangement; further milestone payments may boost the total to $1.7 ...
BioSpace12d
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...
PharmaTimes13d
Gilead and LEO Pharma partner to develop oral STAT6 program
Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...
Gilead, LEO Pharma partner to develop programs for inflammatory diseases
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...
Business Wire14d
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
MedCity News14d
Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target
The drugmaker is paying $250 million up front to acquire preclinical small molecules from LEO Pharma. Gilead will continue development of oral formulations of these potential drugs, while ...
FierceBiotech14d
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
The market potential may be why Gilead is handing over a hefty $250 million upfront pile, with a total $1.7 billion in biobucks (including the upfront payment) on the table for Leo and sales ...